Bosh sahifaCVAC • NASDAQ
add
CureVac BV
3,26 $
Seans yopilganidan keyin:(2,15%)-0,070
3,19 $
Yopilgan:12-iyl, 19:47:42 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
3,27 $
Kunlik diapazon
3,17 $ - 3,39 $
Yillik diapazon
2,22 $ - 10,55 $
Bozor kapitalizatsiyasi
731,24 mln USD
Oʻrtacha hajm
1,45 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (EUR) | mar, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 12,37 mln | 73,56% |
Joriy xarajat | 47,77 mln | -1,92% |
Sof foyda | -70,55 mln | -22,87% |
Sof foyda marjasi | -570,22 | 29,20% |
Har bir ulushga tushum | -0,31 | -14,81% |
EBITDA | -72,22 mln | -28,15% |
Amaldagi soliq stavkasi | -0,95% | — |
Balans
Jami aktivlari
Jami passivlari
| (EUR) | mar, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 300,15 mln | -51,39% |
Jami aktivlari | 690,43 mln | -29,09% |
Jami passivlari | 243,52 mln | -6,44% |
Umumiy kapital | 446,91 mln | — |
Tarqatilgan aksiyalar | 224,31 mln | — |
Narxi/balansdagi bahosi | 1,64 | — |
Aktivlardan daromad | -26,07% | — |
Kapitaldan daromad | -36,84% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (EUR) | mar, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -70,55 mln | -22,87% |
Operatsiyalardan naqd pul | -96,55 mln | 3,04% |
Sarmoyadan naqd pul | -5,09 mln | 61,34% |
Moliyadan naqd pul | -1,12 mln | -100,48% |
Naqd pulning sof oʻzgarishi | -102,30 mln | -184,04% |
Boʻsh pul | -68,47 mln | 25,88% |
Haqida
CureVac N.V. is a German biopharmaceutical company. It develops therapies based on messenger RNA. Headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr, Steve Pascolo, Florian von der Mulbe, Günther Jung, and Hans-Georg Rammensee. CureVac has approximately 375 employees since May 2018.
At the beginning of the COVID-19 pandemic, CureVac was an early starter in the race to develop a German vaccine for protection against COVID-19, caused by infection with the SARS-CoV-2 virus. Clinical trials for the CureVac COVID-19 Vaccine began in June 2020, and in the same month, the German Federal Government invested €300 million in CureVac, with one of the terms of the agreement being that KfW will hold a stake of approximately 23% in the company. In June 2021 the company announced that CVnCoV displayed inadequate results in Phase III clinical trials with only 47% efficacy. In October 2021, the company announced it would be abandon further research and development into CVnCoV and would instead focus its efforts in collaborating with GSK to develop improved mRNA vaccine technology. Wikipedia
Tashkil etilgan
2000
Sayt
Xodimlar soni
1 086
